Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Year-round initiation of Allergovit 6-grasses immunotherapy in seasonal allergic rhinitis or rhinoconjunctivitis
2015-002409-13Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Aug 2015
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Allergovit in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergopharma. Primary endpoint: Safety and tolerability of intraseasonal versus standard dose escalation. Started Aug 2015; status: completed.
02
Drugs
Allergovit
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2015-002409-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002409-13.